T2 Biosystems Announces Patent Covering T2Hemostasis
Published: Feb 05, 2013
LEXINGTON, Mass.--(BUSINESS WIRE)--T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the U.S. Patent and Trademark Office has issued patent 8,344,731 (the ‘731 patent), “NMR device for the detection of analytes”. The patent describes the use of T2MR™ technology to directly detect physical changes within a blood sample, such as coagulation, fibrinolysis, platelet function and other hemostasis properties, as used in T2Hemostasis™ assays. T2Hemostasis is the first technology capable of rapidly characterizing key coagulation, platelet and other hematologic factors directly from whole blood on a single, compact instrument.